Clinical trials: Major Adverse Cardiac Event (MACE)
Major Adverse Cardiac Event (MACE)
How Clinical and Personal Information Shape Physicians' Risk Judgments
Physicians often form quick judgments about the risk for serious disease when interacting with patients. Underestimating risk can lead to underuse of diagnostic testing and untreated illness, which can worsen patient outcomes.
- Trial name
- NCT07162376
- Testing
- Personal Information Disclosure
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Rheumatoid Arthritis, Major Adverse Cardiac Events
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.
- Trial name
- TOFSTAT (NCT07554820)
- Testing
- Tofacitinib 5 MG
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Hypotension, Postoperative Complications
Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery
Major adverse cardiovascular events (MACE) are a leading cause of serious complications and death following major noncardiac surgery.
- Conditions
- Hypotension, Postoperative Complications, Acute Coronary Syndrome, Heart Failure
- Trial name
- BBB (NCT02533128)
- Testing
- Liberal blood pressure management, Tight blood pressure management
- Where
- Switzerland
- Volunteers
- 458 people
- Sponsor
- Miodrag Filipovic, Prof. Dr. med.
Chronic Coronary Syndrome
CTFFR and Prediction of Non-Significant CAD Lesions
In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography…
- Trial name
- NCT06979427
- Testing
- NIFFR
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Shiraz University of Medical Sciences
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease, Stent Restenosis
MACE in Different Drug-Eluting Stents
In this retrospective cohort study, all patients from Iranian registry were recruited and follow up after 5 years were recorded for MACE, and its relation to type and demographic data were evaluated
- Trial name
- NCT06470529
- Testing
- drug eluting stents
- Where
- Iran
- Volunteers
- 4,159 people
- Sponsor
- Shiraz University of Medical Sciences
Left Ventricular Remodeling, Plasma Multi-Omics
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to…
- Conditions
- Left Ventricular Remodeling, Plasma Multi-Omics, Acute ST-segment Elevation Myocardial Infarction, Immunomics
- Trial name
- NCT06885619
- Testing
- Diagnostic Test: echocardiography and blood collection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Major Adverse Cardiovascular Events (MACE), Prevention
Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease
The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target…
- Conditions
- Major Adverse Cardiovascular Events (MACE), Prevention, Coronary Artery Disease(CAD), CT Angiography
- Trial name
- SUCCESS (NCT06843005)
- Testing
- Coronary Computed Tomography Angiography, Current clinical guidelines
- Where
- China
- Volunteers
- 3,100 people
- Sponsor
- Zhang longjiang,MD
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Thrombosis
The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery
This prospective, multicentre, observational study aims to test pre-operative platelet function when taking anti-platelet medications.
- Trial name
- NCT01707459
- Where
- Canada
- Volunteers
- 201 people
- Sponsor
- University Health Network, Toronto
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Hypertension, Stroke
A Cluster-Randomized Controlled Trial
The goal of this study is to learn if an AI-generated personalized health report combined with face-to-face guidance from cardiologists can help rural adults with high blood pressure control their blood pressure better and reduce…
- Conditions
- Hypertension, Stroke, Cardiovascular, Coronary Heart Disease
- Trial name
- NCT07845448
- Testing
- AI-powered personalized health report with cardiologist consultation and prescription optimization, Integrated management (follow-up, education, quality control) without AI report and cardiologist consultation
- Volunteers
- 14,400 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-ST Elevation Myocardial Infarction (NSTEMI), Acute Coronary Syndrome
Left Atrial Strain for Predicting MACE in NSTEMI
This prospective observational study aims to evaluate whether left atrial reservoir strain, measured by two-dimensional speckle tracking echocardiography, independently predicts 6-month major adverse cardiovascular events (MACE)…
- Conditions
- Non-ST Elevation Myocardial Infarction (NSTEMI), Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- NCT07797634
- Volunteers
- 150 people
- Sponsor
- Assiut University
Cardiovascular Events, MACE
Tezspire Cardiac Events PASS
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for…
- Trial name
- TRESPASS (NCT06951867)
- Testing
- Tezepelumab
- Where
- 4 sites in United States, Denmark and 2 more
- Volunteers
- 16,640 people
- Sponsor
- AstraZeneca
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
OSA, ACS - Acute Coronary Syndrome
Impact of OSA on Outcomes in Acute Coronary Syndrome
Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals.
- Conditions
- OSA, ACS - Acute Coronary Syndrome, Major Adverse Cardiac Events
- Trial name
- ISAACS (NCT03793582)
- Testing
- ApneaLink Type III portable sleep study
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- MetroHealth Medical Center
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Chronic Total Occlusion (CTO), Chronic Coronary Syndrome
FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion
Prospective, observational, single-center cohort study Hypothesis Higher myocardial FAPI uptake in CTO patients predicts a greater incidence of major adverse cardiovascular events (MACE) within 12 months after PCI.
- Trial name
- FACT-2 (NCT07020858)
- Testing
- FAPl lmaging
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Lin Zhao
Acute Coronary Syndrome
Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome
Objective: To investigate the relationship between Helicobacter pylori (Hp) infection and the prognosis of acute coronary syndrome (ACS) in a Chinese population and to explore the significance of Hp eradication therapy in…
- Trial name
- NCT02317445
- Volunteers
- 472 people
- Sponsor
- Capital Medical University